rphra
live
S&P 5007,359.9-0.08%
NASDAQ29,220.06-0.43%
DOW51,848.9+0.35%
VIX18.63-4.41%
US10Y4.40-1.98%
EUR/USD1.1361-1.26%
GOLD4,014.5-6.65%
WTI69.62-7.44%
BTC60,676-5.84%
S&P 5007,359.9-0.08%
NASDAQ29,220.06-0.43%
DOW51,848.9+0.35%
VIX18.63-4.41%
US10Y4.40-1.98%
EUR/USD1.1361-1.26%
GOLD4,014.5-6.65%
WTI69.62-7.44%
BTC60,676-5.84%

KTTA

Pasithea Therapeutics Corp.
HealthcareBiotechnologyUSUSDPeers →
$0.56
LiveJun 24, 2026
AI Brief
Market cap
$4.14M
52w range
0.28 – 2.06
P / E
EPS
Volume
305.4K
Revenue · FY

Explain this page

Arphra AI
Business description
· company · SEC profile

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

Founded
IPO
Sep 15, 2021
Employees
4
HQ
Miami Beach, FL
CEO
Tiago Reis Marques
CFO
Exchange
NASDAQ
Fiscal year
Identifiers
· company_identifiers
CIK0001841330
CUSIP70261F103
ISINUS70261F2020
FIGIKTTA US
LEI
Cross-listings
· companies · ISIN
  • KTTAPrimaryNasdaq Stock MarketusUSD$4.14M
  • KTTAWNasdaq Stock MarketusUSD$49.12K
The global universe keeps only the primary listing; the other venues for this security are shown here.